Sponsor

Janssen Inc.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Janssen Inc. appears in 16 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials16
Recruiting shown1
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

16 shown
Golimumab for Adherence in Rheumatoid ArthritisNCT03729349 · lead sponsor · 2019-01-15
COMPLETED
A Study of Participants With Advanced Prostate Cancer in CanadaNCT03501173 · lead sponsor · 2018-04-12
COMPLETED
An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in CanadaNCT02688075 · lead sponsor · 2015-11-13
COMPLETED
Observational Study of Golimumab Intravenous InfusionNCT02390700 · lead sponsor · 2015-02-01
TERMINATED
A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology SettingNCT02364531 · lead sponsor · 2014-09-30
COMPLETED
An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected PatientsNCT01615601 · lead sponsor · 2011-10-01
COMPLETED
Remicade Infusion Management ProgramNCT00723905 · lead sponsor · 2005-08-01
COMPLETED
Biologic Treatment Registry Across CanadaNCT00741793 · lead sponsor · 2002-02-12
COMPLETED
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerNCT04812366 · collaborator · 2021-09-21
RECRUITING
Risk of Breakthrough Symptoms With Long-Acting Injectable MedicationsNCT05473741 · collaborator · 2023-01-11
COMPLETED
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate CancerNCT03902951 · collaborator · 2021-03-17
ACTIVE_NOT_RECRUITING
Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)NCT03298009 · collaborator · 2018-05-01
WITHDRAWN
Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting InjectionNCT03390712 · collaborator · 2018-01-02
UNKNOWN
Use of Canagliflozin in Conjunction With Insulin in a Real-world SettingNCT02681497 · collaborator · 2016-03-01
COMPLETED
Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.NCT02556034 · collaborator · 2015-09-01
COMPLETED
Prucalopride Versus Placebo in GastroparesisNCT02031081 · collaborator · 2014-03-01
COMPLETED

Drugs studied in this sponsor's trials

12 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Janssen Inc. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
abiraterone acetate1
apalutamide1
apalutamide 60 MG Oral Tablet1
atezolizumab1
capivasertib1
docetaxel1
leuprolide acetate1
paliperidone palmitate1

Sponsor roles

collaborator8
lead sponsor8
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.